Compare HUT & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | ALKS |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | N/A | 1991 |
| Metric | HUT | ALKS |
|---|---|---|
| Price | $43.88 | $28.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $51.08 | $42.85 |
| AVG Volume (30 Days) | ★ 7.1M | 1.9M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | 1.89 | ★ 2.02 |
| Revenue | $178,318,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $74.79 | N/A |
| Revenue Next Year | $116.78 | $24.22 |
| P/E Ratio | $23.55 | ★ $14.14 |
| Revenue Growth | ★ 5.60 | 1.08 |
| 52 Week Low | $10.04 | $25.17 |
| 52 Week High | $57.29 | $36.45 |
| Indicator | HUT | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.58 | 46.34 |
| Support Level | $38.36 | $27.69 |
| Resistance Level | $45.64 | $28.53 |
| Average True Range (ATR) | 4.49 | 0.85 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 74.71 | 42.22 |
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.